menu
    • menu
    [{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Granzer Regulatory Consulting | Ticeba GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RHEACELL \/ FGK Clinical Research | Granzer Regulatory Consulting | Ticeba GmbH","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Granzer Regulatory Consulting | Ticeba GmbH"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"RHEACELL \/ FGK Clinical Research"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"8","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"RHEACELL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RHEACELL \/ Undisclosed"},{"orgOrder":0,"company":"RHEACELL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RHEACELL \/ Undisclosed"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ FGK Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"RHEACELL \/ FGK Clinical Research"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH"},{"orgOrder":0,"company":"RHEACELL","sponsor":"AOP Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"allo-APZ2-CVU","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"RHEACELL \/ AOP Health"},{"orgOrder":0,"company":"RHEACELL","sponsor":"AOP Health","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"allo-APZ2-OTS","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RHEACELL \/ AOP Health","highestDevelopmentStatusID":"10","companyTruncated":"RHEACELL \/ AOP Health"},{"orgOrder":0,"company":"RHEACELL","sponsor":"Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LSC2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"}]

    Find Clinical Drug Pipeline Developments & Deals by RHEACELL

    Menu

    RHEACELL

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2-CVU

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : AOP Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rheacell and AOP Health Unite for Butterfly Disease and Venous Wound Therapy

                            Details : The partnership aims to develop and deliver innovative cell therapies, Ebesanar and Amesanar for patients suffering from Butterfly Children’s Disease and Chronic Venous Wounds.

                            Product Name : Amesanar

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : allo-APZ2-CVU

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : AOP Health

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2-OTS

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : AOP Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rheacell and AOP Health Partner to Commercialize Cell Therapies in Europe

                            Details : Under the agreement, AOP will commercialize Rheacell’s two stem cell products, Ebesanar and Amesanar, in Europe, Turkey, Israel and the MENA region.

                            Product Name : Ebesanar

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : allo-APZ2-OTS

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : AOP Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epidermolysis Bullosa.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 01, 2023

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, ...

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epidermolysis Bullosa.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 19, 2022

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Varicose Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 21, 2021

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : FGK Clinical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Acute-On-Chronic Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 01, 2019

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LSC2

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

                            Details : LSC2 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Limbal Stem Cell Deficiency.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 08, 2018

                            Lead Product(s) : LSC2

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Granzer Regulatory Consulting | Ticeba GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Epidermolysis Bullosa Dystrophica.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 18, 2018

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Granzer Regulatory Consulting | Ticeba GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed

                            RHEACELL

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

                            Details : Allo-APZ2 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arterial Occlusive Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 13, 2017

                            Lead Product(s) : allo-APZ2

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth